Keytruda Adds To Women’s Oncology Lead With Endometrial Cancer Data

 
• By Alaric DeArment

Published data showed Merck’s PD-1 inhibitor combined with Eisai’s Lenvima improved survival in the all-comer population of previously treated endometrial carcinoma.

T-cells attacking cancer_1200x675
Merck and Eisai published data in NEJM from the KEYNOTE-775 study of Keytruda/Lenvima in endometrial carcinoma • Source: Shutterstock

More from Anticancer

More from Therapy Areas